Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma
- 4 December 2009
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 220 (3) , 392-400
Abstract
The histopathological diagnosis of high‐grade endometrioid and serous carcinoma of the ovary is poorly reproducible under the current morphology based classification system, especially for anaplastic, high‐grade tumours. The transcription factor Wilms' tumour‐1 (WT1) is differentially expressed among the gynaecological epithelia from which epithelial ovarian cancers (EOCs) are believed to originate. In EOCs, WT1 protein is observed in the majority of serous carcinomas and in up to 30% of endometrioid carcinomas. It is unclear whether the latter is a reflection of the actual incidence of WT1 protein expression in endometrioid carcinomas, or whether a significant number of high‐grade serous carcinomas have been misclassified as endometrioid carcinoma. Several genetic aberrations are reported to occur in EOCs. These include mutation of the TP53 gene, aberrant activation of β‐catenin signalling and loss of PTEN protein expression, among others. It is unclear whether these aberrations are histotype‐specific. The aim of this study was to better define the molecular characteristics of serous and endometrioid carcinomas in an attempt to address the problems with the current histopathological classification methods. Gene expression profiles were analysed to identify reproducible gene expression phenotypes for endometrioid and serous carcinomas. Tissue microarrays (TMA) were used to assess the incidence of TP53, β‐catenin and PTEN aberrations in order to correlate their occurrence with WT1 as an immunohistochemistry based biomarker of serous histotype. It was found that nuclear WT1 protein expression can identify misclassified high‐grade endometrioid carcinomas and these tumours should be reassigned to serous histotype. Although low‐grade endometrioid carcinomas rarely progress to high‐grade carcinomas, a combined WT1‐negative, TP53‐positive immunophenotype may identify an uncommon high‐grade subtype of ovarian endometrioid carcinoma. GEO database: array data accession number GSE6008. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
Funding Information
- Canadian Institutes of Health Research
- Banque de Tissus et de Données of the FRSQ
- Michael Smith Health Research BC
This publication has 47 references indexed in Scilit:
- Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker StudiesPLOS Medicine, 2008
- Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasionCancer, 2008
- Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC)Molecular Carcinogenesis, 2007
- Antisense Suppression of Pygopus2 Results in Growth Arrest of Epithelial Ovarian CancerClinical Cancer Research, 2006
- Discriminating functional and non‐functional p53 in human tumours by p53 and MDM2 immunohistochemistryThe Journal of Pathology, 2005
- Ovarian cancer is a heterogeneous diseaseCancer Genetics and Cytogenetics, 2005
- Origins and molecular pathology of ovarian cancerLaboratory Investigation, 2005
- Intraperitoneal serous adenocarcinoma: A critical appraisal of three hypotheses on its causeAmerican Journal of Obstetrics and Gynecology, 2004
- Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell linesOncogene, 2003
- Expression Profiles of 290 ESTs Mapped to Chromosome 3 in Human Epithelial Ovarian Cancer Cell Lines Using DNA Expression Oligonucleotide MicroarraysGenome Research, 2002